Final 5-year results of the TAXUS II trial: A randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions

Sigmund Silber, Antonio Colombo, Adrian P. Banning, Karl Hauptmann, Janusz Drzewiecki, Eberhard Grube, Dariusz Dudek, Donald S. Baim

Research output: Contribution to journalArticle

Abstract

BACKGROUND-: The TAXUS II trial was designed to evaluate the safety and efficacy of the commercialized slow-release (SR) and an investigation-only moderate-release (MR) polymer-based TAXUS paclitaxel-eluting stent compared with a bare-metal stent for the treatment of de novo coronary lesions. METHODS AND RESULTS-: This prospective, randomized, double-blind, controlled trial enrolled 536 patients in 2 consecutive cohorts to compare TAXUS SR (n=131) and TAXUS MR (n=135) with an identical but uncoated bare-metal stent control (n=270). The present analysis reports final 5-year clinical outcomes of TAXUS II. At 5 years, both TAXUS SR and MR showed superior outcomes compared with control. The 5-year rates of major adverse cardiac events were 27.6%, 20.4%, and 15.1% (P=0.01); rates of target-vessel revascularization were 22.5%, 16.6%, and 9.0% (P=0.004); and rates of target-lesion revascularization were 18.4%, 10.3%, and 4.5% (P

Original languageEnglish
Pages (from-to)1498-1504
Number of pages7
JournalCirculation
Volume120
Issue number15
DOIs
Publication statusPublished - Oct 2009

Keywords

  • Coronary disease
  • Drugs
  • Restenosis
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Final 5-year results of the TAXUS II trial: A randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions'. Together they form a unique fingerprint.

  • Cite this